Form 4: Revolution Medicines General Counsel Sells Shares for Tax Obligations Under Pre-Arranged Plan

Revolution Medicines, Inc.'s General Counsel, Jeff Cislini, sold 1,878 shares of common stock for approximately $39.83 per share to cover tax withholding obligations related to RSU vesting, as disclosed in a recent SEC Form 4 filing.

Summary

• Jeff Cislini, General Counsel of Revolution Medicines, Inc., reported the sale of 1,878 shares of the company's common stock.
• The transaction occurred on June 16, 2025, at a weighted average price of $39.83 per share, resulting in an approximate total sale value of $74,740.74.
• This sale was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy Mr. Cislini's tax withholding obligation upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this reported transaction, Mr. Cislini beneficially owns 56,005 shares of Revolution Medicines common stock.
• The beneficial ownership includes 49,054 RSUs and 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale by an executive to cover tax withholding obligations upon RSU vesting, which is a common and expected event and does not indicate a change in company fundamentals or executive sentiment.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured and non-discretionary transaction rather than a discretionary sale based on new information.
• The stated purpose of the sale was to cover tax withholding obligations related to RSU vesting, which is a routine and expected event for executives receiving equity compensation.

Negatives

• The transaction represents a reduction in the direct common stock holdings of a key executive, although it is for a specific, non-discretionary purpose.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader industry context or trends. It reflects an individual executive's share activity rather than company-wide strategic or operational developments.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a small, routine sale for tax purposes by one executive, not indicative of a change in company prospects.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

Keywords

Revolution Medicines, RVMD, SEC Form 4, Insider Trading, Stock Sale, Jeff Cislini, General Counsel, Rule 10b5-1, Restricted Stock Units, RSU Vesting, Tax Withholding, Employee Stock Purchase Plan